Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma.

Herman JM, Fan KY, Wild AT, Wood LD, Blackford AL, Donehower RC, Hidalgo M, Schulick RD, Edil BH, Choti MA, Hruban RH, Pawlik TM, Cameron JL, Laheru DA, Iacobuzio-Donahue CA, Wolfgang CL.

Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):458-9. doi: 10.1016/j.ijrobp.2013.06.2039. No abstract available.

2.

Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.

Herman JM, Fan KY, Wild AT, Hacker-Prietz A, Wood LD, Blackford AL, Ellsworth S, Zheng L, Le DT, De Jesus-Acosta A, Hidalgo M, Donehower RC, Schulick RD, Edil BH, Choti MA, Hruban RH, Pawlik TM, Cameron JL, Laheru DA, Wolfgang CL.

Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):678-85. doi: 10.1016/j.ijrobp.2013.03.032.

3.

Can we move towards personalised pancreatic cancer therapy?

Jamieson NB, Chang DK, Grimmond SM, Biankin AV.

Expert Rev Gastroenterol Hepatol. 2014 May;8(4):335-8. doi: 10.1586/17474124.2014.893820. Epub 2014 Apr 4. No abstract available.

PMID:
24702631
4.

Preoperative gemcitabine-based chemoradiation therapy for pancreatic ductal adenocarcinoma of the body and tail: impact of splenic vessels involvement on operative outcome and pattern of recurrence.

Takahashi H, Akita H, Gotoh K, Kobayashi S, Marubashi S, Miyoshi N, Sugimura K, Motoori M, Kishi K, Noura S, Fujiwara Y, Ohue M, Ohigashi H, Yano M, Sakon M, Ishikawa O.

Surgery. 2015 Mar;157(3):484-95. doi: 10.1016/j.surg.2014.09.022. Epub 2014 Oct 16.

PMID:
25444512
5.

Effects of perioperative red blood cell transfusion on disease recurrence and survival after pancreaticoduodenectomy for ductal adenocarcinoma.

Kneuertz PJ, Patel SH, Chu CK, Maithel SK, Sarmiento JM, Delman KA, Staley CA 3rd, Kooby DA.

Ann Surg Oncol. 2011 May;18(5):1327-34. doi: 10.1245/s10434-010-1476-3. Epub 2011 Jan 8.

PMID:
21369744
6.

Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.

Knudsen ES, O'Reilly EM, Brody JR, Witkiewicz AK.

Gastroenterology. 2016 Jan;150(1):48-63. doi: 10.1053/j.gastro.2015.08.056. Epub 2015 Sep 15. Review.

7.

The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study.

Shin SH, Kim HJ, Hwang DW, Lee JH, Song KB, Jun E, Shim IK, Hong SM, Kim HJ, Park KM, Lee YJ, Kim SC.

Oncotarget. 2017 Mar 14;8(11):17945-17959. doi: 10.18632/oncotarget.14901.

8.

Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review.

Kim ST, Lee J, Park SH, Lee JK, Lee KT, Lee KH, Heo JS, Choi SH, Choi DW, Park YS, Lim HY, Kang WK, Jang KT, Park HC, Lim DH, Park JO.

Am J Clin Oncol. 2012 Oct;35(5):432-8.

PMID:
21606820
9.

Adjuvant Therapy in Pancreas Cancer: Does It Influence Patterns of Recurrence?

Parikh AA, Maiga A, Bentrem D, Squires MH 3rd, Kooby DA, Maithel SK, Weber SM, Cho CS, Katz M, Martin RC, Scoggins CR, Sutton J, Ahmad SA, Abbott DE, Carr J, Kim HJ, Yakoub D, Idrees K, Merchant N.

J Am Coll Surg. 2016 Apr;222(4):448-56. doi: 10.1016/j.jamcollsurg.2015.12.031. Epub 2016 Feb 16.

PMID:
26895735
10.

A comprehensive examination of Smad4, Smad6 and Smad7 mRNA expression in pancreatic ductal adenocarcinoma.

Singh P, Wig JD, Srinivasan R, Radotra BD.

Indian J Cancer. 2011 Apr-Jun;48(2):170-4. doi: 10.4103/0019-509X.82876.

11.

Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.

Oshima M, Okano K, Muraki S, Haba R, Maeba T, Suzuki Y, Yachida S.

Ann Surg. 2013 Aug;258(2):336-46. doi: 10.1097/SLA.0b013e3182827a65.

PMID:
23470568
12.

Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.

Estrella JS, Rashid A, Fleming JB, Katz MH, Lee JE, Wolf RA, Varadhachary GR, Pisters PW, Abdalla EK, Vauthey JN, Wang H, Gomez HF, Evans DB, Abbruzzese JL, Wang H.

Cancer. 2012 Jan 1;118(1):268-77. doi: 10.1002/cncr.26243. Epub 2011 Jul 6.

13.

SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma.

Singh P, Srinivasan R, Wig JD.

Pancreas. 2012 May;41(4):541-6. doi: 10.1097/MPA.0b013e318247d6af.

PMID:
22504380
14.

Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.

Van Buren G 2nd, Ramanathan RK, Krasinskas AM, Smith RP, Abood GJ, Bahary N, Lembersky BC, Shuai Y, Potter DM, Bartlett DL, Zureikat AH, Zeh HJ, Moser AJ.

Ann Surg Oncol. 2013 Nov;20(12):3787-93. doi: 10.1245/s10434-013-3161-9. Epub 2013 Aug 1.

PMID:
23904005
15.

Adjuvant therapy in pancreatic cancer.

Jones OP, Melling JD, Ghaneh P.

World J Gastroenterol. 2014 Oct 28;20(40):14733-46. doi: 10.3748/wjg.v20.i40.14733. Review.

16.

Genetics and Biology of Pancreatic Ductal Adenocarcinoma.

Dunne RF, Hezel AF.

Hematol Oncol Clin North Am. 2015 Aug;29(4):595-608. doi: 10.1016/j.hoc.2015.04.003. Epub 2015 Jun 10. Review.

PMID:
26226899
17.

Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer.

Combs SE, Habermehl D, Kessel KA, Bergmann F, Werner J, Naumann P, Jäger D, Büchler MW, Debus J.

Ann Surg Oncol. 2014 Aug;21(8):2801-7. doi: 10.1245/s10434-014-3607-8. Epub 2014 Jun 11.

PMID:
24916745
18.

Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy.

Turrini O, Waters JA, Schnelldorfer T, Lillemoe KD, Yiannoutsos CT, Farnell MB, Sarr MG, Schmidt CM.

HPB (Oxford). 2010 Sep;12(7):447-55. doi: 10.1111/j.1477-2574.2010.00196.x.

19.

Genomic Testing for Gemcitabine-Based Treatment of Pancreatic Cancer.

Zhang J, Hochwald SN.

J Natl Cancer Inst. 2016 Feb 8;108(5). pii: djv424. doi: 10.1093/jnci/djv424. Print 2016 May. No abstract available.

PMID:
26857393
20.

A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.

Duffy A, Kortmansky J, Schwartz GK, Capanu M, Puleio S, Minsky B, Saltz L, Kelsen DP, O'Reilly EM.

Ann Oncol. 2008 Jan;19(1):86-91. Epub 2007 Sep 17.

PMID:
17878176

Supplemental Content

Support Center